Ebek, Inc. Issues Voluntary Nationwide Recall of Liviro3, a Product Marketed as a Dietary Supplement

FOR IMMEDIATE RELEASE -- Los Angeles, CA -- January 19, 2007 -- Ebek, Inc., 3921 Wilshire Boulevard, Suite 307, Los Angeles, Ca 90010, announced today that it is conducting a voluntary nationwide recall of the Company's supplement product sold under the name Liviro3.

The Company has been informed by representatives of the Food and Drug Administration (FDA) that lab analysis by FDA of Liviro3 samples found the product contains tadalafil, an FDA-approved drug used to treat erectile dysfunction (ED), making Liviro3 an unapproved drug.

FDA advised that this poses a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels.

According to the FDA, consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.

FDA advises that ED is a common problem in men with these conditions, and they may seek products to enhance sexual performance.

FDA advises that tadalafil, may cause side effects, such as headaches and flushing.

The recalled Liviro3 is sold in 10-tablet boxes or 20-tablet plastic bottles. The product label warns consumers with high blood pressure not to ingest the product but does not state it contains tadalafil.

Consumers who have Liviro3 in their possession should stop using it immediately and contact their physician if they experienced any problem that may be related to taking this product.

The public is encouraged to submit a report of any serious adverse events that occur with the use of Liviro3 to the FDA's MedWatch Adverse Event Reporting program online [at www.fda.gov/MedWatch/report.htm ], by phone [1-800-FDA-1088], or by returning the postage-paid FDA form 3500 [which may be downloaded from www.fda.gov/MedWatch/getforms.htm] by mail [to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787] or fax [1-800-FDA-0178].

Ebek has taken this voluntary action because it is committed to providing accurate information about its products and because of concern for the health and safety of consumers. Ebek is working with the FDA in the recall process. It sincerely regrets any inconvenience to customers.

No illnesses have been reported to the Company to date in connection with this product.

see also:

Warning, Antidepressants 5.2.07 FDA: Update Warning on Antidepressants with info on Suicidal Thinking
FDA: Warning to Antidepressants for Suicidal Thinking in Young Adults

Xolair Warning FDA Proposes to Strengthen Label Warning for Xolair
FDA Proposes Strenger Label Warning for Xolair due to anaphylaxis risk

2007 Health Advisories Pre-made Colistimethate May Link to Cystic Fibrosis Patient's Death
Cystic Fibrosis Patient Dies After Using Pre-Mixed Colistimethate